Celgene profit rises 25 pct up on higher cancer drug sales
July 24, 2014 at 07:50 AM EDT
July 24 (Reuters) - Celgene Corp reported a 25 percent increase in quarterly profit, helped by robust sales of its flagship cancer drug, Revlimid.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.